Ayako Iwamuro | IR |
Christophe Weber | CEO |
Andy Plump | R&D President |
Constantine Saroukos | CFO |
Giles Platford | President of the PDT Business Unit |
Julie Kim | President, U.S. Business Unit & U.S. Country Head |
Ramona Sequeira | President, Global Portfolio Division |
Masato Iwasaki | Representative Director |
Shinichiro Muraoka | Morgan Stanley |
Stephen Barker | Jefferies |
Seiji Wakao | JPMorgan Chase & Co |
Stacy Ku | Cowen and Company |
Fumiyoshi Sakai | Crédit Suisse |
Hidemaru Yamaguchi | Citigroup |
Thank you very much for your participation in Fiscal Year 2021 Earnings webinar of Takeda Pharmaceuticals. I am Ayako Iwamuro, IR of Takeda Pharmaceuticals. [Operator Instructions] Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings.